Eli Lilly's Foundayo Cuts Sleep Apnea Severity By Up To 44% In Phase 3 Trials

Bản dịch chưa sẵn sàng. Đang hiển thị bài viết gốc.

(RTTNews) - Eli Lilly and Company (LLY) on Monday announced positive Phase 3 results showing that its oral obesity drug Foundayo (orforglipron) significantly reduced obstructive sleep apnea (OSA) severity in adults with obesity or overweight.